Champions Oncology, Inc. (CSBR) is a Biotechnology company in the Healthcare sector, currently trading at $5.73. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CSBR = $5.13 (-10.5% from the current price, the stock appears overvalued). Analyst consensus target is CSBR = $12 (+109.4% upside).
Valuation: CSBR trades at a trailing Price-to-Earnings (P/E) of -36.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.18.
Financials: revenue is $57M, +5.4%/yr average growth. Net income is $5M, growing at -315.1%/yr. Net profit margin is 8.3% (thin). Gross margin is 47.3% (-4.6 pp trend).
Balance sheet: total debt is $6M against $4M equity (Debt-to-Equity (D/E) ratio 1.62, leveraged). Current ratio is 0.94 (tight liquidity). Debt-to-assets is 18.9%. Total assets: $32M.
Analyst outlook: 5 / 7 analysts rate CSBR as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 74/100 (Pass), Growth 40/100 (Partial), Past 50/100 (Partial), Health 33/100 (Fail), Moat 34/100 (Fail), Future 85/100 (Pass), Income 45/100 (Partial).
